Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 51 41 14 69
Acute Coronary Syndrome 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:326
NCIt 46 C34738
SNOMED-CT 64 52674009

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to retinal ischemia and limb ischemia, and has symptoms including angina pectoris, muscle weakness and polydipsia. An important gene associated with Ischemia is EGR1 (Early Growth Response 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Pathways in cancer. The drugs Aspirin and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 605)
# Related Disease Score Top Affiliating Genes
1 retinal ischemia 34.0 CASP3 CXCL12 VEGFA
2 limb ischemia 34.0 ACE CXCL12 NOS3 VEGFA
3 vascular disease 32.6 ACE HMOX1 NOS3 PON1 VEGFA
4 microvascular complications of diabetes 5 32.4 ACE NOS3 PON1 VEGFA
5 myocardial infarction 31.9 ACE CASP3 CXCL12 GJA1 MPO NOS3
6 arteries, anomalies of 31.2 ACE NOS3 PON1 VEGFA
7 peripheral artery disease 30.8 ACE NOS3 VEGFA
8 renovascular hypertension 30.4 ACE HMOX1 NOS3
9 vascular dementia 30.4 ACE APP PON1 VEGFA
10 pulmonary edema 30.0 ACE HMOX1 NOS3
11 alzheimer disease 29.8 ACE APP CASP3 CDK5 HMOX1 MPO
12 pulmonary hypertension 29.6 ACE CAV1 NOS3 VEGFA
13 arteriovenous fistula 29.5 EPO HMOX1
14 hepatopulmonary syndrome 29.5 CAV1 HMOX1 NOS3 VEGFA
15 parkinson disease, late-onset 29.4 APP CASP3 CDK5 HMOX1 SOD2
16 brain ischemia 12.3
17 transient cerebral ischemia 12.3
18 critical limb ischemia 12.3
19 chronic myocardial ischemia 12.1
20 coronary artery anomaly 11.4
21 chronic intestinal vascular insufficiency 11.3
22 cerebral hypoxia 11.3
23 hypoxia 11.2
24 ischemic heart disease 11.2
25 arterial calcification, generalized, of infancy, 1 11.2
26 vertebrobasilar insufficiency 11.2
27 myocardial stunning 11.1
28 polyarteritis nodosa, childhood-onset 11.1
29 central retinal vein occlusion 11.1
30 calciphylaxis 11.1
31 microvascular complications of diabetes 1 11.0
32 microvascular complications of diabetes 2 11.0
33 short bowel syndrome 11.0
34 cerebral atherosclerosis 11.0
35 mononeuritis multiplex 11.0
36 cerebritis 10.9
37 legg-calve-perthes disease 10.9
38 sturge-weber syndrome 10.9
39 nonarteritic anterior ischemic optic neuropathy 10.9
40 arterial calcification, generalized, of infancy, 2 10.9
41 lateral medullary syndrome 10.9
42 acute vascular insufficiency of intestine 10.9
43 erythermalgia, primary 10.7
44 exudative vitreoretinopathy 1 10.7
45 exudative vitreoretinopathy 2, x-linked 10.7
46 exudative vitreoretinopathy 4 10.7
47 cerebral amyloid angiopathy, app-related 10.7
48 exudative vitreoretinopathy 3 10.7
49 microvascular complications of diabetes 3 10.7
50 microvascular complications of diabetes 4 10.7

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


angina pectoris, muscle weakness, polydipsia, anoxemia

GenomeRNAi Phenotypes related to Ischemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CASP3 HMOX1 MAP3K5 MPO NOL3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CASP3 HMOX1 MAP3K5 MPO NOL3

MGI Mouse Phenotypes related to Ischemia:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 EGR1 CASP3 ADORA3 EPO CAV1 APP
2 homeostasis/metabolism MP:0005376 10.47 ACE EGR1 CASP3 ADORA3 CDK5 EPO
3 cellular MP:0005384 10.44 EGR1 CASP3 EPO CAV1 APP CXCL12
4 behavior/neurological MP:0005386 10.4 GJA1 ACE EGR1 CASP3 ADORA3 CDK5
5 hematopoietic system MP:0005397 10.39 GJA1 ACE EGR1 CASP3 ADORA3 EPO
6 immune system MP:0005387 10.35 GJA1 ACE EGR1 CASP3 ADORA3 EPO
7 mortality/aging MP:0010768 10.28 GJA1 ACE EGR1 CASP3 CDK5 EPO
8 endocrine/exocrine gland MP:0005379 10.18 ACE CAV1 EGR1 CASP3 GJA1 HMOX1
9 muscle MP:0005369 10.18 CASP3 EPO CAV1 APP CXCL12 GJA1
10 integument MP:0010771 10.16 GJA1 CAV1 EGR1 CASP3 ADORA3 CDK5
11 nervous system MP:0003631 10.1 APP CAV1 EGR1 CASP3 CDK5 CXCL12
12 liver/biliary system MP:0005370 10.09 ACE CAV1 EGR1 EPO CXCL12 HMOX1
13 renal/urinary system MP:0005367 9.81 ACE CAV1 CASP3 ADORA3 HMOX1 NOS3
14 no phenotypic analysis MP:0003012 9.8 CXCL12 APP CASP3 ADORA3 CDK5 GJA1
15 reproductive system MP:0005389 9.7 GJA1 ACE EGR1 CASP3 CAV1 CXCL12
16 respiratory system MP:0005388 9.36 GJA1 EGR1 CASP3 ADORA3 CDK5 EPO

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
2
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
3
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
4
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2 73963-72-1 2754
5
Probucol Approved, Investigational Phase 4,Phase 2 23288-49-5 4912
6
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
7
Capsaicin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 404-86-4 1548943
8
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
9
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
10
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
11
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 46507594 772
12 Nadroparin Approved, Investigational Phase 4 9041-08-1
13
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
14
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 32051 23994
15
Atenolol Approved Phase 4,Phase 3,Phase 2 29122-68-7 2249
16
Nimodipine Approved, Investigational Phase 4,Phase 2 66085-59-4 4497
17
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2 95635-55-5, 142387-99-3 56959
18
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
19
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
20
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
21
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 2713 9552079
22
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
25
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
26
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
27
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
28
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 2833 6167
29
Abciximab Approved Phase 4,Phase 3,Phase 2 143653-53-6
30
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
31
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
33
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
34
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
35
Adenosine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-61-7 60961
36
Nicorandil Approved, Investigational Phase 4,Phase 3 65141-46-0 47528
37
Nicardipine Approved, Investigational Phase 4,Phase 3,Early Phase 1 55985-32-5 4474
38
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
39
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
40
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
41
Varenicline Approved, Investigational Phase 4,Phase 3 249296-44-4 5310966
42
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
43
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
44
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 5460373 44475014 11953898
45
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1 7440-47-3 27668
46
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 54678486 6691
47
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
48
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
49
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
50
Lorazepam Approved Phase 4,Phase 1 846-49-1 3958

Interventional clinical trials:

(show top 50) (show all 10164)

# Name Status NCT ID Phase Drugs
1 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
2 Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Unknown status NCT01104441 Phase 4
3 Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia Unknown status NCT00403780 Phase 4 pregabalin;placebo
4 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
5 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
6 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
7 Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion Unknown status NCT00526695 Phase 4 Sevoflurane (Preconditioning)
8 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
9 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
10 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
11 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
12 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
13 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
14 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
15 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
16 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
17 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
18 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
19 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
20 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
21 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
22 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
23 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
24 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
25 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
26 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
27 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
28 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
29 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
30 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
31 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
32 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
33 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
34 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
35 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
36 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
37 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
38 Ranolazine Loading to Prevent PCI-induced Myocardial Injury Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
39 Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
40 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
41 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
42 Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Unknown status NCT01342822 Phase 4
43 Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population Unknown status NCT01663805 Phase 4 Everolimus
44 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
45 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
46 Effect of Conditioning on Myocardial Damage in STEMI Unknown status NCT02158468 Phase 4
47 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
48 ASCEND: A Study of Cardiovascular Events iN Diabetes Unknown status NCT00135226 Phase 4 aspirin;Omega-3-acid Ethyl Esters;Placebo Aspirin;Placebo omega-3-Ethyl Esters
49 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status NCT00325793 Phase 4 Nicardipine
50 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

38
Heart, Brain, Endothelial, Bone, Liver, Testes, Spinal Cord

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 6465)
# Title Authors Year
1
Acute Limb Ischemia-Much More Than Just a Lack of Oxygen. ( 29373539 )
2018
2
How Do Dendritic Cells Play The Role In Ischemia/Reperfusion Triggered Kidney Allograft Rejection. ( 29446738 )
2018
3
Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( 29452136 )
2018
4
Effects of molsidomine on retinal ischemia/reperfusion injury in rabbits. ( 29323543 )
2018
5
Long-term treadmill exercise improves memory impairment through restoration of decreased synaptic adhesion molecule 1/2/3 induced by transient cerebral ischemia in the aged gerbil hippocampus. ( 29341891 )
2018
6
Protective effects of D-Limonene against transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 29399074 )
2018
7
Reduced Intravoxel Incoherent Motion Microvascular Perfusion Predicts Delayed Cerebral Ischemia and Vasospasm After Aneurysm Rupture. ( 29439196 )
2018
8
VEGF mitigates histone induced pyroptosis in the remote liver injury associated with renal allograft ischemia-reperfusion injury in rats. ( 29446207 )
2018
9
Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis. ( 29449333 )
2018
10
Endovascular Distal Plantar Vein Arterialization in Dialysis Patients With No-Option Critical Limb Ischemia and Posterior Tibial Artery Occlusion: A Technique for Limb Salvage in a Challenging Patient Subset. ( 29264998 )
2018
11
Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia. ( 29395424 )
2018
12
Ischemia Reperfusion Injury after Gradual versus Rapid Flow Restoration for Middle Cerebral Artery Occlusion Rats. ( 29374244 )
2018
13
The Incidence, Risk Factors, and Outcomes of Contrast-Induced Nephropathy In Patients With Critical Limb Ischemia Following Lower Limb Angiography. ( 29390867 )
2018
14
Role of Complement Properdin in Renal Ischemia-Reperfusion Injury. ( 29446739 )
2018
15
A de novo Ser111Thr variant in aquaporin-4 in a patient with intellectual disability, transient signs of brain ischemia, transient cardiac hypertrophy, and progressive gait disturbance. ( 29437797 )
2018
16
Magnesium sulphate induces preconditioning in preterm rodent models of cerebral hypoxia-ischemia. ( 29355709 )
2018
17
Blood rheology of angina pectoris patients with myocardial injury after ischemia reperfusion and its effect on thromboxane B<sub>2</sub>levels. ( 29399084 )
2018
18
Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. ( 29386474 )
2018
19
Surgical revascularization of the celiac artery for persistent intestinal ischemia in short bowel syndrome. ( 29247810 )
2018
20
Neutralization of CD95 ligand protects the liver against ischemia-reperfusion injury and prevents acute liver failure. ( 29374146 )
2018
21
MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulating TLR4/TRAF6/NF-I_B pathway. ( 28771774 )
2018
22
Natural language processing of clinical notes for identification of critical limb ischemia. ( 29425639 )
2018
23
Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia. ( 29242062 )
2018
24
Activation of JAK/STAT3 restores NK-cell function and improves immune defense after brain ischemia. ( 29401578 )
2018
25
Spinal Cord Stimulation Improves the Microvascular Perfusion Insufficiency Caused by Critical Limb Ischemia. ( 29377343 )
2018
26
cGAS-mediated autophagy protects the liver from ischemia/reperfusion injury independent of STING. ( 29446653 )
2018
27
PROGRESSION OF RETINAL ISCHEMIA IN A CASE OF MACULAR TELANGIECTASIA TYPE 1 AFTER RANIBIZUMAB INJECTION: OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS. ( 29443804 )
2018
28
Neuronalinjury and roles of apoptosis and autophagy in a neonatal rat model of hypoxia-ischemia-induced periventricular leukomalacia. ( 29436652 )
2018
29
Eriodictyol Attenuates Myocardial Ischemia-Reperfusion Injury through the Activation of JAK2. ( 29441020 )
2018
30
Electroacupuncture preconditioning protects against focal cerebral ischemia/reperfusion injury<i>via</i>suppression of dynamin-related protein 1. ( 29451211 )
2018
31
Faim2 contributes to neuroprotection by erythropoietin in transient brain ischemia. ( 29315561 )
2018
32
Protective effects of beef decoction rich in carnosine on cerebral ischemia injury by permanent middle cerebral artery occlusion in rats. ( 29399121 )
2018
33
Clinical Outcomes after Isolated Infrapopliteal Revascularization in Hemodialysis Patients with Critical Limb Ischemia: Endovascular Therapy versus Bypass Surgery. ( 29367521 )
2018
34
SUMOylation in brain ischemia: Patterns, targets, and translational implications. ( 29148315 )
2018
35
Gene-Modified Mesenchymal Stem Cell-Based Therapy In Renal Ischemia-Reperfusion Injury. ( 29446737 )
2018
36
Chronic intermittent hypoxia promotes myocardial ischemia-related ventricular arrhythmias and sudden cardiac death. ( 29445096 )
2018
37
Vinpocetine protects inner retinal neurons with functional NMDA glutamate receptors against retinal ischemia. ( 29106899 )
2018
38
The protective effect of alpha-lipoic acid against brain ischemia and reperfusion injury via mTOR signaling pathway in rats. ( 29432779 )
2018
39
Evaluation of maternal serum ischemia modified albumin and total antioxidant status in ectopic pregnancy. ( 29284337 )
2018
40
Layer-specific global longitudinal strain reveals impaired cardiac function in patients with reversible ischemia. ( 29446126 )
2018
41
Renal Decapsulation Prevents Intrinsic Renal Compartment Syndrome in Ischemia-Reperfusion-Induced Acute Kidney Injury: A Physiologic Approach. ( 29341964 )
2018
42
Acute Limb Ischemia Secondary to Native Artery Occlusion: Results of a Contemporary Case Series. ( 29404750 )
2018
43
Regulation and mechanism of miR-146 on renal ischemia reperfusion injury. ( 29441948 )
2018
44
Efficacy Outcomes of Endovascular Versus Surgical Revascularization in Critical Limb Ischemia: Results From a Prospective Cohort Study. ( 29355026 )
2018
45
Mesenchymal stem cells protect against hypoxia-ischemia brain damage by enhancing autophagy through BDNF/mTOR signaling pathway. ( 29451335 )
2018
46
Myeloid differentiation protein 2 induced retinal ischemia reperfusion injury via upregulation of ROS through a TLR4-NOX4 pathway. ( 29111459 )
2018
47
Self-retaining barbed suture reduces warm ischemia time during laparoscopic partial nephrectomy. ( 29448861 )
2018
48
Cryptogenic acute limb ischemia: a retrospective cohort study defining a previously undescribed clinical entity. ( 29357035 )
2018
49
Treatment with Uric Acid Reduces Infarct and Improves Neurologic Function in Female Mice After Transient Cerebral Ischemia. ( 29398531 )
2018
50
Reactive Oxygen Species Play a Biphasic Role in Brain Ischemia. ( 29420085 )
2018

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 CASP3 CAV1 CXCL12 MAP3K5 NOS3 PRKAA2
2 12.69 CASP3 CXCL12 EPO HMOX1 VEGFA
3
Show member pathways
12.55 CASP3 CDK5 EGR1 MAP3K5 NOS3
4
Show member pathways
12.32 ADORA3 CASP3 CAV1 CXCL12 EGR1 EPO
5
Show member pathways
12.09 CASP3 EGR1 MAP3K5 VEGFA
6 11.99 CASP3 EGR1 GJA1 VEGFA
7 11.89 CASP3 CDK5 EGR1 PRKAA2
8
Show member pathways
11.7 CAV1 NOS3 VEGFA
9 11.67 EPO HMOX1 NOS3 VEGFA
10
Show member pathways
11.64 CASP3 CXCL12 MAP3K5
11 11.62 CASP3 EGR1 NOS3 VEGFA
12 11.52 CASP3 GJA1 MAP3K5 NOS3 PRKAA2
13 11.4 EPO NOS3 VEGFA
14 11.37 CXCL12 EPO HMOX1 VEGFA
15
Show member pathways
11.3 APP CDK5 SOD2
16 11.24 CAV1 HMOX1 MAP3K5 NOS3 PRKAA2 VEGFA
17 11.11 GJA1 HMOX1 NOS3

GO Terms for Ischemia

Cellular components related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ACE APP CXCL12 EPO HMOX1 MPO
2 membrane raft GO:0045121 9.26 APP CASP3 CAV1 GJA1
3 caveola GO:0005901 8.8 CAV1 HMOX1 NOS3

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 APP CAV1 EGR1 GJA1 VEGFA
2 angiogenesis GO:0001525 9.95 CAV1 HMOX1 NOS3 VEGFA
3 apoptotic process GO:0006915 9.92 APP CASP3 CDK5 EPO GJA1 HMOX1
4 response to oxidative stress GO:0006979 9.84 APP HMOX1 MPO SOD2
5 cholesterol metabolic process GO:0008203 9.83 APP PON1 PRKAA2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 APP CAV1 VEGFA
7 response to lipopolysaccharide GO:0032496 9.83 CASP3 EPO GJA1 MPO SOD2
8 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.82 EGR1 EPO VEGFA
9 protein oligomerization GO:0051259 9.82 CAV1 GJA1 NOL3
10 response to wounding GO:0009611 9.81 ADORA3 CASP3 CDK5
11 apoptotic signaling pathway GO:0097190 9.81 CASP3 CAV1 MAP3K5
12 response to glucose GO:0009749 9.8 CASP3 EGR1 GJA1
13 regulation of macroautophagy GO:0016241 9.8 CASP3 CDK5 PRKAA2
14 negative regulation of cell proliferation GO:0008285 9.8 ADORA3 APP CAV1 GJA1 HMOX1 NOS3
15 response to estrogen GO:0043627 9.79 CAV1 EPO HMOX1
16 positive regulation of protein binding GO:0032092 9.78 APP CAV1 CDK5
17 negative regulation of apoptotic process GO:0043066 9.76 CASP3 EPO HYOU1 MPO NOL3 PRKAA2
18 response to hydrogen peroxide GO:0042542 9.75 CASP3 HMOX1 SOD2
19 neuron apoptotic process GO:0051402 9.72 APP CASP3 CDK5
20 regulation of blood pressure GO:0008217 9.71 ACE HMOX1 NOS3 SOD2
21 positive regulation of neuron death GO:1901216 9.7 CDK5 EGR1 MAP3K5
22 blood vessel remodeling GO:0001974 9.69 ACE NOL3 NOS3
23 positive regulation of T cell migration GO:2000406 9.67 APP CXCL12
24 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.67 NOL3 SOD2
25 induction of positive chemotaxis GO:0050930 9.67 CXCL12 VEGFA
26 positive regulation of peptidase activity GO:0010952 9.66 APP CAV1
27 positive regulation of blood vessel diameter GO:0097755 9.63 GJA1 HMOX1 NOS3
28 response to fluid shear stress GO:0034405 9.62 GJA1 NOS3
29 positive regulation of chemokine biosynthetic process GO:0045080 9.6 EGR1 HMOX1
30 positive regulation of axon extension involved in axon guidance GO:0048842 9.59 CXCL12 VEGFA
31 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.57 ACE VEGFA
32 negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway GO:1903298 9.56 HYOU1 NOL3
33 removal of superoxide radicals GO:0019430 9.54 MPO NOS3 SOD2
34 smooth muscle hyperplasia GO:0014806 9.49 HMOX1 NOS3
35 regulation of the force of heart contraction by chemical signal GO:0003057 9.48 CAV1 NOS3
36 response to ischemia GO:0002931 9.43 CAV1 EGR1 GJA1 HYOU1 MAP3K5 NOL3
37 response to hypoxia GO:0001666 9.28 CASP3 CAV1 CXCL12 EGR1 EPO HMOX1

Molecular functions related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.9 ACE APP EGR1 HMOX1 MAP3K5 MPO
2 death receptor binding GO:0005123 9.26 CASP3 NOL3
3 receptor binding GO:0005102 9.02 APP CAV1 CXCL12 GJA1 NOL3
4 peptidase activator activity GO:0016504 8.96 APP CAV1

Sources for Ischemia